Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2 CALM TAB is a fixed-dose combination pharmaceutical product containing alprazolam and propranolol hydrochloride. Alprazolam is a benzodiazepine that functions as a positive allosteric modulator of the GABA-A receptor, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system to provide anxiolytic, sedative, and muscle relaxant properties. Propranolol is a non-selective beta-adrenergic receptor antagonist that blocks the action of epinephrine and norepinephrine on both beta-1 and beta-2 receptors, thereby reducing the peripheral physical symptoms of anxiety such as tachycardia, tremors, and palpitations. This combination is marketed by Zoic Lifesciences, a generic pharmaceutical company based in India, and is typically indicated for the management of anxiety disorders, particularly when autonomic symptoms are prominent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alprazolam + propranolol.